The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors
Open accessAbstract
Multiple approaches presently aim to combine targeted therapies using tyrosine kinase inhibitors with immunotherapy. Ex vivo-generated dendritic cells are frequently used in such strategies due to their unique ability to initiate primary T-cell immune responses. Besides governing tumor cell growth, many kinases targeted by tyrosine kinase inhibitors are involved in the development and function of dendritic cells and thus tyrosine kinase inhibitor therapy may cause immunoinhibitory side effects. We here report that exposure of developing human monocyte-derived dendritic cells to the BCR-ABL inhibitors imatinib, dasatinib, and nilotinib results in profound upregulation of the transmembrane glycoprotein osteoactivin that has recently been characterized as a negative regulator of T-cell activation. Thus, in line with osteoactivin upregulation, exposure to tyrosine kinase inhibitors resulted in significantly reduced stimulatory capacity of dendritic cells in mixed lymphocyte reactions that could be restored by the addition of blocking anti-osteoactivin antibody. Our data demonstrate that tyrosine kinase inhibitor-mediated inhibition of dendritic cell function is, at least in great part, mediated by upregulation of the immune inhibitory molecule osteoactivin.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other urinary protein biomarkers (α-klotho and osteoactivin (GPNMB)) have previously demonstrated utility as predictive markers of biological age and senescent cell load, and have been altered by senolytic intervention in previous preclinical and clinical populations.
“Further, there are other urinary protein biomarkers (i.e. α-klotho and osteoactivin (GPNMB)) that may have great value in future clinical senolytic trials, which have previously demonstrated utility as predictive markers of biological age [72] and senescent cell load [73]. Both have successfully been altered by senolytic intervention in previous preclinical and clinical populations [73,74].”
From Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease (2025) · cites this paper as [74]
Cites
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304 · see citing works
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,659 · see citing works
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,618 · see citing works
Evolving concepts of rheumatoid arthritis
Firestein, G. S. (2003) · Nature · doi:10.1038/nature01661 · Cited by 3,601 · see citing works
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713 · see citing works
Mellman, I., & Steinman, R. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00449-4 · Cited by 2,256 · see citing works
Kawai, T., & Akira, S. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401850 · Cited by 1,817 · see citing works
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D. J., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,785 · see citing works
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G. N., Kim, D., Issaragrisil, S., le Coutre, P., Étienne, G., Lobo, C. L. D. C., Pasqüini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,670 · see citing works
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H. M., Shah, N. P., Hochhaus, A., Cortes, J. E., Shah, S. A., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasqüini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,572 · see citing works
Mahon, F., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F. E., Legros, L., Charbonnier, A., Guerci‐Bresler, A., Varet, B. R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,541 · see citing works
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H. M., Giles, F. J., Wunderle, L., Bhalla, K. N., O'Brien, S. M., Waßmann, B., Tanaka, C., Manley, P. W., Rae, P., Mietlowski, W. L., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,334 · see citing works
Buchdunger, E., Cioffi, C. L., Law, N. M., Stover, D. R., Ohno-Jones, S., Druker, B. J., & Lydon, N. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,272 · see citing works
Induction of tolerance by IL-10-treated dendritic cells
Steinbrink, K., Wölfl, M., Jonuleit, H., Knop, J., & Enk, A. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.10.4772 · Cited by 1,245 · see citing works
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,060 · see citing works
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036 · see citing works
Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Müller, M. C., Radich, J. P., Rudoltz, M. S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.38 · Cited by 855 · see citing works
Bhatia, R., Holtz, M. S., Niu, N., Gray, R., Snyder, D., Sawyers, C. L., Arber, D. A., Slovak, M. L., & Forman, S. J. (2003) · Blood · doi:10.1182/blood-2002-09-2780 · Cited by 543 · see citing works
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D. J., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 524 · see citing works
Cancer Immunotherapy by Dendritic Cells
Melief, C. J. M. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.004 · Cited by 505 · see citing works
Karikó, K., Bhuyan, P. K., Capodici, J., & Weissman, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6545 · Cited by 446 · see citing works
Interleukin-10 Receptor Signaling through the JAK-STAT Pathway
Riley, J. K., Takeda, K., Akira, S., & Schreiber, R. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16513 · Cited by 401 · see citing works
de Labarthe, A., Rousselot, P. H., Huguet, F., Delabesse, É., Witz, F., Maury, S., Réa, D., Cayuela, J., Vekemans, M. C., Reman, O., et al. (2006) · Blood · doi:10.1182/blood-2006-03-011908 · Cited by 345 · see citing works
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Li, J., Rix, U., Fang, B., Bai, Y., Edwards, A., Colinge, J., Bennett, K. L., Gao, J., Song, L., Eschrich, S. A., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.332 · Cited by 279 · see citing works
TRAIL/Apo-2-ligand-induced apoptosis in human T cells
Jeremias, I., Herr, I., Böhler, T., & Debatin, K. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01 · Cited by 265 · see citing works
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Hantschel, O., Rix, U., & Superti-Furga, G. (2008) · Leukemia & Lymphoma · doi:10.1080/10428190801896103 · Cited by 256 · see citing works
Brossart, P., Schneider, A., Dill, P. E., Schammann, T., Grünebach, F., Wirths, S., Kanz, L., Bühring, H., & Brugger, W. (2001) · PubMed · Cited by 201 · see citing works
Self-citationShikano, S., Bonkobara, M., Zukas, P. K., & Ariizumi, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008539200 · Cited by 166 · see citing works
Appel, S., Boehmler, A. M., Grünebach, F., Müller, M., Rupf, A., Weck, M. M., Hartmann, U., Reichardt, V. L., Kanz, L., Brümmendorf, T. H., et al. (2003) · Blood · doi:10.1182/blood-2003-03-0975 · Cited by 163 · see citing works
Self-citationBrossart, P., Grünebach, F., Stuhler, G., Reichardt, V. L., Möhle, R., Kanz, L., & Brugger, W. (1998) · Blood · doi:10.1182/blood.v92.11.4238 · Cited by 156 · see citing works
Self-citationCloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts
Safadi, F. F., Xu, J., Smock, S. L., Rico, M. C., Owen, T. A., & Popoff, S. N. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1259 · Cited by 154 · see citing works
DC-HIL is a negative regulator of T lymphocyte activation
Chung, J., Sato, K., Dougherty, I. I., Cruz, P. D., & Ariizumi, K. (2007) · Blood · doi:10.1182/blood-2006-11-053769 · Cited by 133 · see citing works
Saglio, G. N., Hochhaus, A., Goh, Y. T., Masszi, T., Pasqüini, R., Maloisel, F., Erben, P., Cortes, J. E., PAQUETTE, R. L., Bradley‐Garelik, M. B., et al. (2010) · Cancer · doi:10.1002/cncr.25123 · Cited by 127 · see citing works
Nicholson, G. C., Malakellis, M., Collier, F., Cameron, P. U., Holloway, W. R., Gough, T. J., Gregorio-King, C. C., Kirkland, M. A., & Myers, D. E. (2000) · PubMed · Cited by 119 · see citing works
Brossart, P., Zobywalski, A., Grünebach, F., Behnke, L., Stuhler, G., Reichardt, V. L., Kanz, L., & Brugger, W. (2000) · PubMed · Cited by 117 · see citing works
Self-citationSyndecan-4 Mediates the Coinhibitory Function of DC-HIL on T Cell Activation
Chung, J., Dougherty, I. I., Cruz, P. D., & Ariizumi, K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.5778 · Cited by 114 · see citing works
NICHOLSON, G. C., MALAKELLIS, M., COLLIER, F. M., CAMERON, P. U., HOLLOWAY, W. R., GOUGH, T. J., GREGORIO-KING, C., KIRKLAND, M. A., & MYERS, D. E. (2000) · Clinical Science · doi:10.1042/cs0990133 · Cited by 107 · see citing works
Appel, S., Rupf, A., Weck, M. M., Schoor, O., Brümmendorf, T. H., Weinschenk, T., Grünebach, F., & Brossart, P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1713 · Cited by 80 · see citing works
Self-citationKarikó, K., Bhuyan, P. K., Capodici, J., Ni, H., Lubinski, J. M., Friedman, H. M., & Weissman, D. (2004) · Cells Tissues Organs · doi:10.1159/000079987 · Cited by 77 · see citing works
The DC‐HIL/syndecan‐4 pathway inhibits human allogeneic T‐cell responses
Chung, J., Bonkobara, M., Tomihari, M., Cruz, P. D., & Ariizumi, K. (2009) · European Journal of Immunology · doi:10.1002/eji.200838990 · Cited by 73 · see citing works
Tyrosine kinases as targets for the treatment of rheumatoid arthritis
Swanson, C., Paniagua, R. T., Lindström, T. M., & Robinson, W. H. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.82 · Cited by 73 · see citing works
Tebib, J. G., Xavier Mariette, A., Bourgeois, P., Flipo, R., Gaudin, P., Loët, X. L., Gineste, P., Guy, L., Mansfield, C. D., Moussy, A., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2740 · Cited by 68 · see citing works
BCR-ABL Activity Is Critical for the Immunogenicity of Chronic Myelogenous Leukemia Cells
Brauer, K. M., Werth, D., von Schwarzenberg, K., Bringmann, A., Kanz, L., Grünebach, F., & Brossart, P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0302 · Cited by 49 · see citing works
Self-citationNeumann, F., Herold, C., Hildebrandt, B., Kobbe, G., Aivado, M. A., Rong, A., Free, M., Rössig, R., Fenk, R. R., Schneider, P., et al. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.02811.x · Cited by 40 · see citing works
Knödler, A., Schmidt, S., Bringmann, A., Weck, M. M., Brauer, K. M., Holderried, T. A. W., Heine, A.-K., Grünebach, F., & Brossart, P. (2008) · Leukemia · doi:10.1038/leu.2008.301 · Cited by 36 · see citing works
Self-citationTyrosine kinases as targets in rheumatoid arthritis
Tristano, A. G. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2008.09.010 · Cited by 23 · see citing works
Eklund, K. K., Lindstedt, K. A., Sandler, C., Kovanen, P. T., Laasonen, L., Juurikivi, A., Wolff, H., Mykkänen, M., & Joensuu, H. (2008) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e318188b1ce · Cited by 21 · see citing works
Resolution of Rheumatoid Arthritis Symptoms With Imatinib Mesylate
Vernon, M. R., Pearson, L., & Atallah, E. L. (2009) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e3181b0d352 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Role of GPNMB in Inflammation
Saade, M., Araujo de Souza, G., Scavone, C., & Kinoshita, P. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674739 · Cited by 216 · see citing works
Siegel, P. M., Rose, A. A. N., Annis, M. G., & Maric (2013) · OncoTargets and Therapy · doi:10.2147/ott.s44906 · Cited by 149 · see citing works
Gong, X.-M., Li, Y., Luo, J., Wang, J., Wei, J. N., Wang, J.-Q., Xiao, T., Xie, C., Hong, J., Ning, G., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0065-4 · Cited by 93 · see citing works
GPNMB: a potent inducer of immunosuppression in cancer
Lazaratos, A.-M., Annis, M. G., & Siegel, P. M. (2022) · Oncogene · doi:10.1038/s41388-022-02443-2 · Cited by 78 · see citing works
Chen, H., Wang, Y., Bai, C., & Wang, X. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.01.027 · Cited by 65 · see citing works
The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells
Gutknecht, M. F., Geiger, J., Joas, S., Dörfel, D., Salih, H. R., Müller, M., Grünebach, F., & Rittig, S. M. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0099-5 · Cited by 63 · see citing works
Self-citationKobayashi, M., Chung, J., Beg, M. S., Arriaga, Y. E., Verma, U. N., Courtney, K. D., Mansour, J. C., Haley, B., Khan, S. A., Horiuchi, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0330 · Cited by 64 · see citing works
Generation and functional characterization of MDSC-like cells
Heine, A., Held, S. A. E., Schulte-Schrepping, J., Wolff, J. F. A., Klee, K., Ulas, T., Schmacke, N. A., Daecke, S. N., Riethausen, K., Schultze, J. L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1295203 · Cited by 48 · see citing works
Self-citationKolb, E. A., Gorlick, R. G., Billups, C. A., Hawthorne, T. R., Kurmasheva, R. T., Houghton, P. J., & Smith, M. A. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25099 · Cited by 43 · see citing works
GPNMB is expressed in human epidermal keratinocytes but disappears in the vitiligo lesional skin
Biswas, K. B., Takahashi, A., Mizutani, Y., Takayama, S., Ishitsuka, A., Yang, L., Yang, F., Iddamalgoda, A., Katayama, I., & Inoue, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-61931-1 · Cited by 43 · see citing works
Sheng, M. H. ‐., Wergedal, J. E., Mohan, S., Amoui, M., Baylink, D. J., & Lau, K. ‐. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035280 · Cited by 27 · see citing works
Murata, K., Yoshino, Y., Tsuruma, K., Moriguchi, S., Oyagi, A., Tanaka, H., Ishisaka, M., Shimazawa, M., Fukunaga, K., & Hara, H. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.13010 · Cited by 24 · see citing works
Zhou, Y., Kaminski, H. J., Gong, B., Cheng, G., Feuerman, J. M., & Kusner, L. L. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-14422 · Cited by 20 · see citing works
Wölfl, M., Schwinn, S., Yoo, Y.-E., Reß, M. L., Braun, M., Chopra, M., Schreiber, S. C., Ayala, V. I., Öhlén, C., Eyrich, M. K., et al. (2013) · Blood · doi:10.1182/blood-2013-03-488072 · Cited by 20 · see citing works
Garbarino, V. R., Palavicini, J. P., Melendez, J., Barthelemy, N. R., He, Y., Kautz, T. F., Lopez-Cruzan, M., Mathews, J. J., Xu, P., Zhang, B., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00591 · Cited by 19 · see citing works
“Both have successfully been altered by senolytic intervention in previous preclinical and clinical populations [73,74].”
Baerveldt, E. M., Onderdijk, A. J., Kurek, D., Kant, M., Florencia, E. F., IJpma, A. S., van der Spek, P. J., Bastiaans, J., Jansen, P. A. M., van Kilsdonk, J. W. J., et al. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12175 · Cited by 18 · see citing works
Wang, Q., Kuroda, Y., Yang, L., Lai, S., Mizutani, Y., Iddamalgoda, A., Guo, J., Yamamoto, A., Murase, D., Takahashi, Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910843 · Cited by 17 · see citing works
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation
Geier, B., Kurmashev, D., Kurmasheva, R. T., & Houghton, P. J. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00193 · Cited by 16 · see citing works
Ramani, V., Teshima, T., Tamura, K., Chung, J., Kobayashi, M., Cruz, P. D., & Ariizumi, K. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.05.012 · Cited by 16 · see citing works
Fu, C., Luo, J., Ye, S., Yuan, Z., & Li, S. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00303 · Cited by 13 · see citing works
Nerreter, T., Köchel, C., Jesper, D., Eichelbrönner, I., Putz, E., Einsele, H., & Seggewiß-Bernhardt, R. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.05.010 · Cited by 11 · see citing works
Dörfel, D., Lechner, C. J., Joas, S., Funk, T., Gutknecht, M. F., Salih, J., Geiger, J., Kropp, K. N., Maurer, S., Müller, M., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2129-9 · Cited by 11 · see citing works
Self-citationKaminski, H. J., Himuro, K., Alshaikh, J., Gong, B., Cheng, G., & Kusner, L. L. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00524 · Cited by 9 · see citing works
Wehrstedt, S., Kubis, J., Zimmermann, A., Bruns, H., Mayer, D., Grieshober, M., & Stenger, S. (2018) · European Journal of Immunology · doi:10.1002/eji.201847656 · Cited by 8 · see citing works
The janus-faced biology of GPNMB: from tissue homeostasis to cancer pathogenesis
Long, C., Li, Y., Yuan, M. D., & Al-Sultan, I. I. A. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1664764 · Cited by 8 · see citing works
Funk, T., Fuchs, A. R., Altdörfer, V., Klein, R., Autenrieth, S. E., Müller, M. R. A., Salih, H. R., Henes, J. C., Grünebach, F., & Dörfel, D. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13439 · Cited by 8 · see citing works
Self-citationPrevention and synergistic control of Ph+ ALL by a DNA vaccine and 6-mercaptopurine
Köchling, J., Rott, Y., Arndt, S., Marschke, C., Schmidt, M., Wittig, B., Kalies, K., Westermann, J., & Henze, G. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.037 · Cited by 8 · see citing works
Nishida, N., Otsu, M., Mizutani, Y., Ishitsuka, A., Mizukami, Y., & Inoue, S. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108299 · Cited by 7 · see citing works
Can anthocyanins improve maintenance therapy of Ph+ acute lymphoblastic leukaemia?
Köchling, J., Schmidt, M., Rott, Y., Sagner, M., Ungefroren, H., Wittig, B., & Henze, G. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12071 · Cited by 6 · see citing works
Current perspectives on the therapeutic aspects of chronic myelogenous leukemia
Bhaskar, A., Raturi, K., Dang, S., & Gabrani, R. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.953056 · Cited by 5 · see citing works
Schmidt, M. J., Altdörfer, V., Schnitte, S., Fuchs, A. R., Kropp, K. N., Maurer, S., Müller, M., Salih, H. R., Rittig, S. M., Grünebach, F., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.03.001 · Cited by 5 · see citing works
Self-citationGPNMB promotes proliferation of developing eosinophils
Hwang, S. M., Kang, J. H., Kim, B. K., Uhm, T. G., Kim, H. J., Lee, H.-H., Binas, B., & Chung, I. Y. (2017) · The Journal of Biochemistry · doi:10.1093/jb/mvx002 · Cited by 3 · see citing works
The expression and function of Gpnmb in lymphatic endothelial cells
Kronk, T. A., Ernesto Solorzano, Z., Robinson, G. T., Castor, J., Ball, H. C., & Safadi, F. F. (2024) · Gene · doi:10.1016/j.gene.2024.148993 · Cited by 1 · see citing works
The Anti-Inflammatory Role of GPNMB in Post-Traumatic OsteoarthritisPreprint
Al-Adlaan, A. A., Cook, B. P., Hussein, N. J., Jaber, F. A., Kronk, T. A., Ernesto Solorzano, Z., Frangiamore, S. J., Ball, H. C., & Safadi, F. F. (2025) · eLife · doi:10.7554/elife.107696.2 · Cited by 1 · see citing works
Novel Therapies on the Horizon
Cripe, T. P., Haworth, K. B., & Houghton, P. J. (2015) · Pediatric oncology · doi:10.1007/978-3-319-18099-1_15
Psoriasis: Molecular targets of denervation and therapy
Baerveldt, E. M. (2013) · RePub (Erasmus University Rotterdam)
The Anti-Inflammatory Role of GPNMB in Post-Traumatic OsteoarthritisPreprint
Al-Adlaan, A. A., Cook, B. P., Hussein, N. J., Jaber, F. A., Kronk, T. A., Ernesto Solorzano, Z., Frangiamore, S. J., Ball, H. C., & Safadi, F. F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.06.658389
The Anti-Inflammatory Role of GPNMB in Post-Traumatic OsteoarthritisPreprint
Al-Adlaan, A. A., Cook, B. P., Ernesto Solorzano, Z., Hussein, N. J., Jaber, F. A., Kronk, T. A., Frangiamore, S. J., Ball, H. C., & Safadi, F. F. (2025) · eLife · doi:10.7554/elife.107696.1
The Anti-Inflammatory Role of GPNMB in Post-Traumatic OsteoarthritisPreprint
Al-Adlaan, A. A., Cook, B. P., Hussein, N. J., Jaber, F. A., Kronk, T. A., Ernesto Solorzano, Z., Frangiamore, S. J., Ball, H. C., & Safadi, F. F. (2025) · eLife · doi:10.7554/elife.107696
Protein tyrosine kinases in dendritic cell-mediated anti-cancer immunity
Mao, M., Zhao, L., Kroemer, G., Kepp, O., & Liu, P. (2026) · Seminars in Immunology · doi:10.1016/j.smim.2026.102037
Carfilzomib preserves dendritic cell phenotype and function compared with bortezomib
Wang, L., Dahlfrancis, M., Dörfel, D., Walz, J. S., Klatt, M. G., Grünebach, F., & Rittig, S. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1936021
Self-citation
- Authors
- Schwarzbich, M.-A., Gutknecht, M., Salih, J., Salih, H. R., Brossart, P., Rittig, S. M., & Grünebach, F.
- Affiliations
- University of Tübingen (DE)
- University of Bonn (DE)
- Corresponding author
- Grünebach, Frank
- ORCID
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2011-08-27
- Volume
- 61
- Issue
- 2
- Pages
- 193-202
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11028554
- OpenAlex
- W1966693183
- Cited by
- 42
- References
- 48
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 5 · 2017: 2 · 2016: 1 · 2015: 3 · 2014: 5 · 2013: 4 · 2012: 4
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Krebshilfe
- European Social Fund
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- GPNMB, BCR-ABL tyrosine kinase inhibitors, monocyte-derived dendritic cells, imatinib, dasatinib, nilotinib, immune inhibitory receptors, T cell activation, mixed lymphocyte reaction, immunotherapy side effects, combination therapy
- MeSH terms
- Imatinib Mesylate, Dasatinib, Antibodies, Monoclonal, Benzamides, Cells, Cultured, Dendritic Cells, Humans, Immunotherapy, Lymphocyte Culture Test, Mixed, Lymphocyte Activation, Membrane Glycoproteins, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, T-Lymphocytes, Thiazoles, Up-Regulation, Fusion Proteins, bcr-abl, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
